Gerald J Dal Pan (Gerald Dal Pan)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 16

Top Topics

Multiple Myeloma

Clinical Evaluation

Drug Administration

Top Venues

Clinical pharmacology and therapeutics

JMIR public health and surveillance

Pharmacoepidemiology and drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Monica A Muñoz, Gerald J Dal Pan, Yu-Jung Jenny Wei, Hong Xiao, Chris Delcher, Andrew Giffin, Nabila Sadiq, Almut G Winterstein
Sociodemographic Characteristics of Adverse Event Reporting in the USA: An Ecologic Study. Drug safety 47 (4) (2024)
Monica A Muñoz, Gerald J Dal Pan, Yu-Jung Jenny Wei, Hong Xiao, Chris Delcher, Andrew Giffin, Nabila Sadiq, Almut G Winterstein
Sociodemographic Characteristics of Adverse Event Reporting in the USA: An Ecologic Study. Drug safety 47 (4) (2024)
Monica A Muñoz, Gerald J Dal Pan, Yu-Jung Jenny Wei, Hong Xiao, Chris Delcher, Andrew Giffin, Nabila Sadiq, Almut G Winterstein
Sociodemographic Characteristics of Adverse Event Reporting in the USA: An Ecologic Study. Drug safety 47 (4) (2024)
Monica A Muñoz, Gerald J Dal Pan, Yu-Jung Jenny Wei, Hong Xiao, Chris Delcher, Andrew Giffin, Nabila Sadiq, Almut G Winterstein
Sociodemographic Characteristics of Adverse Event Reporting in the USA: An Ecologic Study. Drug safety 47 (4) (2024)
Ameet Sarpatwari, Zhigang Lu, Massimiliano Russo, Heidi Zakoul, Su Been Lee, Gita A Toyserkani, Esther H Zhou, Cynthia LaCivita, Katherine Hyatt Hawkins Shaw, Laura Zendel, Gerald J Dal Pan, Aaron S Kesselheim
How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians. Clinical pharmacology and therapeutics (2024)
Monica A Muñoz, Gerald J Dal Pan, Yu-Jung Jenny Wei, Hong Xiao, Chris Delcher, Andrew Giffin, Nabila Sadiq, Almut G Winterstein
Sociodemographic Characteristics of Adverse Event Reporting in the USA: An Ecologic Study. Drug safety (2024)
Monica A Muñoz, Gerald J Dal Pan, Yu-Jung Jenny Wei, Hong Xiao, Chris Delcher, Andrew Giffin, Nabila Sadiq, Almut G Winterstein
Sociodemographic Characteristics of Adverse Event Reporting in the USA: An Ecologic Study. Drug safety 47 (4) (2024)
Ameet Sarpatwari, Zhigang Lu, Massimiliano Russo, Heidi Zakoul, Su Been Lee, Gita A Toyserkani, Esther H Zhou, Cynthia LaCivita, Katherine Hyatt Hawkins Shaw, Laura Zendel, Gerald J Dal Pan, Aaron S Kesselheim
How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians. Clinical pharmacology and therapeutics 115 (6) (2024)
Judith C Maro, Michael D Nguyen, Joy Kolonoski, Ryan Schoeplein, Ting-Ying Huang, Sarah K Dutcher, Gerald J Dal Pan, Robert Ball
Six Years of FDA's Postmarket Active Risk Identification and Analysis System (ARIA) in the Sentinel Initiative: Implications for Real World Evidence Generation. Clinical pharmacology and therapeutics (2023)
Mohamed Mohamoud, Carmen Cheng, Debra Ryan, Ivone Kim, Eileen Wu, Monica Muñoz, Cindy Kortepeter, Ellen Pinnow, Gerald J Dal Pan
Assessment of the Impact of Mandated Postmarketing Pediatric-Focused Safety Reviews on Safety-Related Regulatory Actions 2013-2019. Clinical pharmacology and therapeutics (2023)
Ida-Lina Diak, Kimberley Swank, Kate McCartan, Maya Beganovic, James Kidd, Neha Gada, Rachna Kapoor, Lisa Wolf, Laura Kangas, Jo Wyeth, Toni Salvatore, Melina Fanari, Andrew A LeBoeuf, Poonam Mishra, Michael D Blum, Gerald J Dal Pan
The Food and Drug Administration's (FDA's) Drug Safety Surveillance During the COVID-19 Pandemic. Drug safety (2022)
Esther H Zhou, Zhou Feng, Ellen Pinnow, Joann Lee, Daniel Bak, Travis Ready, Gerald J Dal Pan
Trend changes of national zolpidem users and exposure cases after FDA drug safety communications. Pharmacoepidemiology and drug safety 30 (11) (2021)
Kathryn Marwitz, S Christopher Jones, Cindy M Kortepeter, Gerald J Dal Pan, Monica A Muñoz
An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System. Drug safety 43 (5) (2021)
Monica A Muñoz, Gerald J Dal Pan, Yu-Jung Jenny Wei, Chris Delcher, Hong Xiao, Cindy M Kortepeter, Almut G Winterstein
Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility. Drug safety 43 (4) (2021)
Monica A Muñoz, Gerald J Dal Pan
The Impact of Litigation-Associated Reports on Signal Identification in the US FDA's Adverse Event Reporting System. Drug safety 42 (10) (2020)
Michael S Sinha, Clark C Freifeld, John S Brownstein, Macarius M Donneyong, Paula Rausch, Brian M Lappin, Esther H Zhou, Gerald J Dal Pan, Ajinkya M Pawar, Thomas J Hwang, Jerry Avorn, Aaron S Kesselheim
Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. JMIR public health and surveillance 4 (1) (2018)